Lupilopram 10mg Jubilant treats serious depression, panic disorders (3 blisters x 10 tablets)
Dosage form Box of 3 blisters x 10 tablets
Specifications Escitalopram
Ingredient
| Composition information | Content |
| Escitalopram | 10mg |
Uses
indications
lupilopram 10mg drug indicated in the following cases:
EscitalPram is a selective inhibitor of Serotonin reabsorption (5-HT) with strong affinity with the main link position. The drug is also associated with the eccentric location on serotonin transportation, with an affinity than 1000 times.
5-HT reabsorption inhibitor is the only mechanism of effect that can explain the pharmacological and clinical effects of Escitalopram.
pharmacokinetics
absorption:
The drug is absorbed almost completely and does not depend on the food (the average time the drug achieves the maximum agriculture after the dosage (average TMAX) is 4 hours).
Like a mixture of racemic citalopram, the absolute bioavailability of Escitalopram is about 80%.
Distribution:
The distribution volume of the drug (VAD, β/F) after taken about 12 to 26 l/kg. Escitalopram and its main metabolites bind to plasma proteins below 80%.
Metabolism:
EscitalPram is metabolized in the liver to form Demethylate and Didemethylate metabolites. Both compounds have pharmacological effects.
In addition, nitrogen may be oxidized to form n-oxide metabolites. Both the original substance and the metabolites are partially eliminated in the form of glucuronide elephants.After taking multiple doses of concentration of Demethyl and Didemethyï specialized chemicals, the same is usually between 28-31% and
The biological transformation of Escitalopram to form Demethylate metabolites mainly through CYP2C19. Some other enzymes that can participate are CYP3A4 and CYP2D6.
Era:
The waste sale time (T1/2β) of the drug after drinking multi -dose is about 30 hours and the plasma clearance coefficient of oral (oral Clina) is about 0.6 l/min.
Main metabolites have a significant longer selling time. EscitalPram and main metabolites are thought to be except for both liver (metabolism) and kidneys, mainly eliminated in the form of metabolites through urine.
pharmacokinetics of linear drugs. Plasma drug concentration in a stable state is achieved after about 1 week.
Average concentration of about 30 nmol/l (from 20 to 125 nmol/l) of the drug in the state of Wen Dinh is achieved at a dose of 10 mg daily.
Before taking Lupilopram 10mg Jubilant treats serious depression, panic disorders (3 blisters x 10 tablets)
How to use
Lupilopram 10mg oral medicine.
EscitalPram is used for single doses per day and can be used or not with food.
Dosage
adults
Safety of dose over 20 mg per day has not been proven.
Dosage to treat serious depression:
Dosage to treat social anxiety disorders:
Compared to behavioral cognitive treatment, this therapy has not been evaluated. Drug treatment is part of the treatment goal.
Dosage dose for spreading anxiety disorders:
Elderly (> 65 years):
Avoid interrupting the treatment suddenly. When stopping treatment with EscitalPram, the dose must be reduced slowly for at least 1 to 2 weeks to reduce the risk of interrupted symptoms. If the symptoms still occur after a decrease in the dose or after treatment, the previous dose must be reviewed. After that, the doctor may continue to reduce the dose, but with a gradual level.
Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.
What to do when overdose?
Toxicity:
Clinical data on the overdose of Escitalopram is very limited and in many cases related to overdose use simultaneously with other drugs.
In most cases that have been reported, no symptoms or mild symptoms.
Very rare reports on deaths due to overdose of Escitalopram; Most cases are related to overdose of other drugs.
With the single dose of EscitalPram from 400 to 800 mg without any serious symptoms
Symptoms:
Dizziness, tremor, agitation, Serotonin syndrome, convulsions, coma, nausea/vomiting, hypotension, fast heart rate, prolonged qt, arrhythmia, hypotension, sodium hypotension.
Treatment of overdose symptoms:
There is no specific antidote. Set and maintain breathing gas to ensure adequate oxygen and respiratory function. Gastric and coal should be used to absorb poison. Stomach was done as soon as possible after taking the medicine.
Need to monitor the expression of the heart and organs together with the treatment support for symptoms.
In an emergency, call the 115 emergency center immediately or go to the nearest local health station.
What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.
Side Effects
The most common harmful reactions in the first week or the second week of drug treatment, the level and frequency often decrease when continuing treatment.
The known harmful reactions of SSRI drugs have also been reported to Escitalopram in controlled studies with clinical fake or spontaneous events after the drug is circulated on the market listed below and classified by agency group and frequency encountered. The frequency is based on clinical studies; Not as exact as placebo.
The frequency is as follows: Very common (≥ 1/10), common (≥ 1/100 to
Blood disorders and lymphatic systems:
immune system disorders:
Endocrine disorders:
Eye disorders:
Cardiovascular disorders:
Urinary system disorders:
Common disorders and body condition:
2: These side effects have been reported to SSRIs.
There have been cases that have been reported to extend the QT period during the period after the drug is used on the market, mainly in patients who had previously suffered from heart disease. In a double blind ECG study, controlled control with fake in healthy people, the fundamental change of QTC interval (exactly according to Fridericia) is 4.3 millisites at a dose of 10 mg daily and 10.7 milloses at a dose of 30 mg daily.
Pharmacological epidemic studies, seeing off on 50 -year -old and older patients, showing an increase in the risk of fractures in patients treated with SSRIs and TCA drugs. The mechanism of fractures is still unknown.
Symptoms of interruption when stopping treatment. Do not continue the treatment of SSRIs/SNRI (Special) drugs often lead to interrupted symptoms.
Dizziness, sensory disorders (including unusual feelings and electric shock), sleep disorders (sleeping eyes and nightmares), agitation or worry, nausea or vomiting, tremor, confusion, sweating, headache, urine, fast heartbeat, unstable bran, irritability and visual disorders are the most common report reaction.
In general, these symptoms from mild to medium and recover, however, in some patients these symptoms may be worse or prolonged. Therefore, when being sent by Escitalopram, it is necessary to reduce the dose slowly.
Instructions on how to handle ADR:
The usual ADRs during the first or second treatment week and often decrease in intensity and frequency.
It is not recommended to use Serotonin re -absorption inhibitors for children under 18 years old because it is easy to commit suicide and aggressive behavior. If used must be closely monitored to detect suicide symptoms.
Some cases of panic when using EscitalPram have an anxiety reaction often at the beginning of treatment. This naughty reaction usually drops after the first 2 weeks of treatment. To reduce the risk of this reaction should take low doses at the initial treatment.
If convulsions appear, it is necessary to stop treating with Escitalopram. Avoid using EscitalPram for patients with non -decision epilepsy.
Use EscitalPram cautious for patients with a history of manic, stopping the drug when a manic attack appears.
Serotonin syndrome and malignant sedative syndrome: stop evadram, serotonin hypertensis, dopamine anti -dopamine drugs (including anti -psychotic drugs) and symptomatic treatment, monitoring tight mental signs.
Non -specific treatment, using dantrolen or bromocryptin is a dopamine owner who can help.
Sudden stopping syndrome: Avoid sudden stopping of the drug, gradually reducing the dose for 1-2 weeks. If there is symptom of a sudden stopping syndrome when the dose is reduced or stopped, it is necessary to re -use the previous treatment doses until the symptoms are over and reduce the weight of weight step by step.
Warnings
Before using the drug you need to read the instructions carefully and refer to the information below.
contraindicated
Lupilopram 10mg drug contraindicated in the following cases:
Be cautious when using
The following special caution warnings applies to SSRI drug groups (Serotonin re -absorption inhibitors):
Used in children and teenagers under 18 years old
Do not take medicine for children and teenagers under 18 years old. Actions related to suicide (suicide gloves and suicide thoughts), and hostility (the main attitude that causes wood, opposite and anger) is more often found in clinical trials in children and teenagers treated with anti -mucus drugs compared to placebo patients.
However, if based on the need for clinical treatment, it still decides to take the drug; The patient is carefully monitored because of the symptoms related to suicide.
In addition, there is still lack of data on safety in the castle in children and teenagers related to development, maturity, awareness and election.
The opposite anxiety
Some patients with panic disorders may increase anxiety symptoms when they start treatment with antidepressants. The opposite reaction usually reduces in the next 2 weeks of treatment. Low starting dose should be used to reduce the effects of anxiety.
epilepsy
Do not continue to use EscitalPram if the patient has a seizure for the first time, or if the frequency of seizures (in patients with a history of epilepsy). Do not use SSRIs in patients with unstable epilepsy, and patients with epilepsy should be closely monitored.
Halfy
Be cautious to use SSRIs in patients with a history of manic/mild mania. Do not continue using SSRIs in patients who begin to revive.
diabetes
Patients with diabetes, treated with SSRIs may change blood sugar control (hypoglycemia or hyperglycemia). Need to adjust the oral dose of insulin/hypoglycemic drugs.
suicide/suicide thoughts or worse status
Depression is involved in increasing suicide thoughts, harming yourself and suicide (issues related to suicide). This risk still exists until the disease is significantly improved. If the disease does not improve in the first few weeks of treatment or more treatment, the patient must be closely monitored until the disease is improved. Clinical experience in general shows the risk of suicide that can increase in the early stages of the recovery period.
Other mental cases that EscitalPrams can also be related to increasing risks. The event is related to suicide. Moreover, these cases have the same serious depression disorders. Be cautious when treating with patients with severe depression and observation monitoring in patients with other depression disorders.
Patients with a history of suicidal issues, or patients who manifest suicide thoughts of significant severity before starting to treat grass risks that have suicidal thoughts or want to commit more, thus must be carefully monitored during treatment.
Analysis after the placebo on clinical trials for antidepressants in mental mental disorders shows the risk of increasing behavior that want to commit suicide when being treated with antidepressants compared to patients younger than 25 years old, is regreased with placebo. It is necessary to closely monitor these patients, especially patients at high risk after taking the drug during the first treatment and after the dose changes.
Must notify patients (and patient care) about the need to monitor any worse condition that appears clinically, behavior or thoughts that want to commit suicide and abnormal changes in behavior and need the doctor's advice immediately if these symptoms appear.
Increasing hyperactivity/psychology
Using SSRIs/SNRIS drugs involved in hyperactivity, characterized by subjective discomfort or non -stop and weighing, it is often accompanied by a restless throne. These symptoms usually occur in some obedience. Patients who manifest these symptoms, increasing the dose may be harmful
Hemorrhage reduction
Hemorrhage reduction, possibly due to the non -corresponding anti -hormone secretion (SIADN), rarely see the report when using SSRIs and generally have to stop treatment. Be cautious in high -risk patients, such as in the elderly group, cirrhosis patients, or in combination with other drugs that can cause sodium hypoglycemia.
Bleeding
There have been reports on subcutaneous bleeding abnormalities, such as bruising and hemorrhage when taking SSRIs. Caution should be careful for patients who are taking SSRIs, especially using anticoagulant drugs, or drugs that affect the function of platelets, (for example, non -typical anti -mental drugs, phenothiazine drugs, most three -ring antidepressants, acetylsalicylic acids and nonsteroidal drugs (NSAIDs), ticlopidine and dipyridamole) bleeding.
ECT (Electric convulsions)
Less has clinical experience on simultaneous treatment of SSRIs with ECT therapy. Therefore, be careful when using the drug.
Serotonin syndrome
Be careful when taking EscitalPram and other drugs that work on Serotonergic systems such as Sumatriptan or Triptan, Tramadol and Tryptophan drugs.
Very rare cases, Serotonin syndrome appears in patients taking SSRIs along with other drugs on Serotonergic systems. Combining symptoms, such as agitation, tremor, muscle jerky and body temperature shows signs of development of this syndrome. If occurred, it is necessary to stop treating with SSRIs and drugs on the Serotonergic system immediately and starting to treat symptoms.
st. John’s World
SHOULD UNDERSION SSRIs and herbal treatment, including St. Plants. John’s World (Hypericum Perforatum) can increase the rate of harmful reactions.
Symptoms of interruption when stopping drugs
Sudden symptoms when stopping the drug in general are common, especially if suddenly stopped. In clinical trials for events that catch gums in the process of stopping the drug about 25% in patients treated with EscitalPram and about 15% in the placebo group.
The risk of sudden symptoms depends on a number of factors such as drug use, dose and dosage reduction. Dizziness, sensory disorders (including abnormal feelings and electric shock), sleep disorders (loss of "sleep and dream), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, urine, fast heartbeat, emotional stability, irritability and visual whip are the most common reports of these symptoms; More.
Symptoms often appear in the first number of weeks not to continue treating, but very rare reports on the above symptoms in patients who forget to take the drug.
In general, these symptoms are self -limited and the naked eye goes for 2 weeks, although in some patients these symptoms may last longer (2 to 3 months or more). Therefore, EscitalPrams should be used to reduce the dose slowly from continuing to treat for a few weeks or months according to the patient's needs (see the "Sudden symptoms when not treated").
Coronary artery disease
Because of the clinical experience is limited, so be careful in patients with coronary artery disease.
The ability to drive and operate machinery
Information about the effect of lupilopram drugs on drivers and operating the machine is being updated.
Women during pregnancy and nursing mothersWarning ratings
au tga Pregnancy category: c
us FDA Pregnancy Category: c
Pregnancy:
There are very little clinical data related to EscitalPram treatment for pregnant women.
Escitalopram toxicity studies on mice's fertility, affecting embryos - fetuses, shows that it does not increase the rate of deformities. Do not use EscitalPram during pregnancy except it is necessary and spend after considering the need for kidneys between risk/efficiency.
The infant must be monitored if the mother in the late stages of the pregnancy using EscitalPram especially in three months of pregnancy. Sudden drugs must be avoided during pregnancy.The following symptoms may occur for babies after using SSRI/SNRI drugs for mothers in the late stage of pregnancy: Emergency respiratory respiratory, purple blue, convulsions, unstable body temperature, difficulty eating, vomiting, hypertonic, weakness, weakness, increased reflexes, tremor, restlessness, sleep, sleep, sleep, sleep, sleep, sleep, sleep, sleep Enjoy of Serotonergic system or non -continuous symptoms.
Most cases of complications started immediately or very early (
Data on pharmacological epidemiology shows the use of SSRI drugs in pregnant women, especially in the end may increase the risk of pulmonary hypertension existing in infants (PPHN). This risk is encountered in about 5 cases in 1,000 pregnant women. In the general population, it is from 1 to 2 cases of PPHN in 1000 pregnant women.
Breastfeeding period:
EscitalPram in lupilopram can be excreted into breast milk.
Therefore, do not take the drug during breastfeeding.
Interactive drug
Contraindicated Lupilopram with the following drugs because of their interactive reactions:
The non -selective inhibitors are not recovered
There have been reports on serious reactions in the following cases: Patients treated with SSRI drugs combined with an unsatisfactory inhibitor without restoring monoamine oxidase enzyme (MA MAII). Recent patients have not continued to treat with SSRI and began to switch to Maoi. In some cases, patients show signs of serotonin syndrome.
Contraindicated EscitalPram in combination with non -selective, non -recovery drugs. It is possible to start treating Escitalopram 14 days after not treating with non -recovery drugs. At least 7 days after not treated with EscitalPram, before starting with an unstable drug, no recovery.
Mao-A inhibitors, recovery (moclobemid)
Because the risk of serotonin syndrome is contraindicated, the combination of Escitalopram with a Mao-A inhibitors like Moclobemid. If the combination is necessary, it must be started with the minimum recommended dose and clinically closely monitored.
Not selective inhibitors, recovery (Linezolid)
Linezolid antibiotics are an inhibitor, not selected with recovery and not used for patients treated with Escitalopram. If the combination is necessary, must be used with the smallest dose and closely monitored clinically.
Selective inhibitors, no recovery Mao-B (Selegiline)
When used in combination with Selegiline, be cautious because of the risk of serotonin syndrome. The dose of Selegiline up to 10mg/day is safe to use in combination with a mixture of racemic citalopram.
Caution used when combined with:
The drugs acting on the Serotonergic System
Concentrated with drugs acting on Serotonergic systems (for example, tramadol, sumatriptan and other triptan) can cause serotonergic syndrome.
Medications reduce epilepsy threshold
SSRIs can reduce epilepsy threshold. It is necessary to be cautious when used simultaneously with drugs that also reduce epilepsy threshold (for example, antidepressants (groups of 3 rounds, SSRI drugs), sedative drugs (phenothiazine, thioxanthene and butyrophenone), MeFloquine, Bupropion and Tramadol).
lithium, tryptophan
There has been an increase in the increased effect on simultaneous use of SSRIs along with lithium or tryptophan, so be careful when using SSRIs simultaneously with other drugs.
st. John’s World
Single use of SSRIs combined with herbal treatment includes St. John ° S Wort (Hypericum Perforatum) can increase the rate of harmful reactions.
Bleeding
The effect of anticoagulants may occur when used in combination with vaccines with anticoagulant drugs. Patients being treated with anticoagulants must be carefully monitored when they start or stop treating EscitalPram. Simultaneous use with non-dabinitis (NSAIDs) may increase the risk of bleeding.
alcohol
No pharmacokinetic or pharmacokinetic interaction between EscitalPram and alcohol. However, like other mind -oriented drugs, do not take alcohol when taking the drug.
Storage
Leave a cool place, avoid light, temperature below 30⁰C.
Other drugs
- ARCOXIA 120MG TABLETS
- BIPHASIC ISOPHANE INSULIN INJECTION BP (PORCINE)
- ESPUMISAN 100 MG/1ML ORAL DROPS EMULSION
- EPILIM SYRUP 200MG/5ML
- MERONEM IV 1G
- WHITE LINIMENT B.P.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions